FDA Grants Osimertinib Priority Review for Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer

Osimertinib demonstrates improved progression-free survival for stage 3 epidermal growth factor receptor-mutated (EGFRm) lung cancer.

Related Keywords

,Suresh Ramalingam ,Osimertinib Tagrisso ,National Cancer Institute ,Winship Cancer Institute Of Emory University ,Astrazeneca ,Executive Director ,Winship Cancer Institute ,Emory University ,New Standard ,